Credit Suisse’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Credit Suisse’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-61,300	Closed	-$50K	–	4731
2015 Q1	$50K	Sell	61,300 -109,500	-64%	-$90.2K	﹤0.01%	4280
2014 Q4	$137K	Buy	+170,800	New	+$156K	﹤0.01%	4374

Other funds holding PVCT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Credit Suisse's PVCT Position: Q2 2015 in Review

Credit Suisse sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q2 2015, closing a stake of 61,300 shares — an estimated $50K sold.

Credit Suisse first reported a position in PVCT in Q4 2014 and held it in 2 quarters. The position peaked at $137K in Q4 2014. 36 funds tracked by Wall St. Rank hold PVCT as of Q2 2015.

Credit Suisse reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q2 2015 after selling out during the quarter.
Credit Suisse sold 61,300 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q2 2015, an estimated $50K.
Credit Suisse first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 2 quarters.
Credit Suisse's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $137K in Q4 2014.
36 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q2 2015.

Based on Credit Suisse's 13F filing for Q2 2015, filed 13 Aug 2015.